In Australia, newly-diagnosed patients aged 18 years and over with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) will now have affordable access to Sprycel (dasatinib) as a first line oral therapy, when this is integrated with chemotherapy, Bristol-Myers Squibb (NYSE: BMY) revealed on Sunday.
Patients with Ph+ALLwill be able to accessSprycel via Australia’s Pharmaceutical Benefits Scheme (PBS) from August 1.
This PBS listing for Sprycel marks a world first, as Australia is the only country with reimbursement approval in this setting. The listing represents a commitment by B-MS to providing more options for Australian clinicians treating rare cancers, particularly patients with limited treatment options, the US pharma major stated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze